Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in the 2024 Bank of America Healthcare Conference to discuss their novel therapeutic for treating Alzheimer's disease. The event will take place on May 15, 2024, and can be accessed via a live webcast on their website.

CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com 

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals participate in the 2024 Bank of America Healthcare Conference?

Acumen Pharmaceuticals will participate in the 2024 Bank of America Healthcare Conference on May 15, 2024.

What is the focus of Acumen Pharmaceuticals' novel therapeutic?

Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

Where can the live webcast of the conference be accessed?

The live webcast of the conference can be accessed under the Investors tab on Acumen Pharmaceuticals' website at www.acumenpharm.com.